- Home
- AGIO vs AMSC Comparison
AGIO vs AMSC Comparison
Compare AGIO & AMSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- AMSC
- Stock Information
- Founded
- AGIO 2007
- AMSC 1987
- Country
- AGIO United States
- AMSC United States
- Employees
- AGIO N/A
- AMSC N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- AMSC Metal Fabrications
- Sector
- AGIO Health Care
- AMSC Consumer Discretionary
- Exchange
- AGIO Nasdaq
- AMSC Nasdaq
- Market Cap
- AGIO 1.4B
- AMSC 1.1B
- IPO Year
- AGIO 2013
- AMSC 1991
- Fundamental
- Price
- AGIO $35.00
- AMSC $53.75
- Analyst Decision
- AGIO Buy
- AMSC Strong Buy
- Analyst Count
- AGIO 6
- AMSC 3
- Target Price
- AGIO $57.40
- AMSC $33.67
- AVG Volume (30 Days)
- AGIO 840.6K
- AMSC 1.2M
- Earning Date
- AGIO 07-31-2025
- AMSC 07-30-2025
- Dividend Yield
- AGIO N/A
- AMSC N/A
- EPS Growth
- AGIO N/A
- AMSC N/A
- EPS
- AGIO 11.13
- AMSC 0.39
- Revenue
- AGIO $40,875,000.00
- AMSC $254,886,000.00
- Revenue This Year
- AGIO $18.94
- AMSC $20.26
- Revenue Next Year
- AGIO $201.70
- AMSC $12.73
- P/E Ratio
- AGIO $3.15
- AMSC $136.18
- Revenue Growth
- AGIO 30.57
- AMSC 63.73
- 52 Week Low
- AGIO $23.42
- AMSC $13.98
- 52 Week High
- AGIO $62.58
- AMSC $57.86
- Technical
- Relative Strength Index (RSI)
- AGIO 38.99
- AMSC 77.22
- Support Level
- AGIO $37.09
- AMSC $43.24
- Resistance Level
- AGIO $39.12
- AMSC $57.86
- Average True Range (ATR)
- AGIO 1.78
- AMSC 2.55
- MACD
- AGIO -0.67
- AMSC 0.88
- Stochastic Oscillator
- AGIO 9.16
- AMSC 78.44
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.